Strong intellectual property (IP) protection is a key element for securing a vibrant life sciences industry. Self-replicating
samples, other progeny issues, and a web of complex, very expensive and time-intensive health and safety regulatory issues
contribute to the particular vulnerabilities of this industry.
Currently, Canada might be summarily characterized as in both "pending" and "spending" mode for IP issues in the life sciences
industry. Pending applies to a critical biotech patent decision anticipated from our Supreme Court; a technical legislative
fix to save the validity of hundreds of patents; and the development of domestic legislation to implement an international
decision promoting access to medicines for countries in need. Spending (always an apt term in this industry) refers to the
increased fees at the Canadian Intellectual Property Office (CIPO) as well as to our new Prime Minister Paul Martin's comments
about the importance of funding our biotech industry to build a 21st century economy.
Canada generally offers broad protection for IP. As with most other developed nations, Canada has ratified and incorporated
into domestic law the major IP treaties, including the Paris Convention, the Patent Cooperation Treaty, the World Trade Organization's
Agreement on Trade-Related Aspects of Intellectual Property (TRIPS), and the Budapest Treaty relating to deposits of microorganisms
(Table 1). Canada also has regulations, in force since March 12, 1993, linking regulatory approval of a generic product to
the patent status of the applicable patented medicine.1 The regulations prescribe a process to determine infringement issues on a preliminary basis while a generic product undergoes
regulatory approval. Canada is, however, struggling through some interpretation and application issues - including the patentability
of higher life forms and protection of confidential information submitted to the government for regulatory approval.
Pending: Life-Form Patentability
On the issue of higher life forms, in December 2002 the Supreme Court rejected claims to the genetically modified Harvard
oncomouse.2 In a 5 to 4 split decision, the majority held that the definition of "invention" in the Patent Act3 did not include a higher life form. Among other things, the "composition of matter" and "manufacture" elements of this definition
did not imply conscious, sentient living creatures. The Court invited Parliament to amend the Patent Act if suchcreatures
were to be accorded patent protection. Claims for other aspects of the invention, including the cell cultures and plasmids,
were held to be properly patentable subject matter. In the minority opinion, Justice Ian Binnie observed that one would look
"in vain" for any distinction in the "invention" definition between Canada and several other countries where the oncomouse
enjoys patent protection. He also noted that the majority view resulted in "disappearing subject matter patentability" between
"two successive stages of a transgenic mouse's genetically preprogrammed growth,"4 namely the egg (patentable) and the mouse (not patentable).
This year opened with biotech patent issues yet again before the Supreme Court.5 This time, the issue centers on
genetically modified canola found growing on Percy Schmeiser's farm in Bruno, Saskatchewan in 1998. Monsanto alleged that
Schmeiser was infringing its patent by growing the herbicide-resistant canola (known as Roundup Ready Canola). Monsanto's
patent claims a gene, and plant cells containing the gene, that confers glyphosate resistance to the plant cell transformed
with the gene. The patent does not contain claims to the plant itself. In the two courts below, Schmeiser's canola plants
were found to infringe the claims to the gene and to the plant cells. This issue is now before the Supreme Court.
Table 1. Canada is a member of several international IP treaties.
The patentability of higher life forms, what is in fact a higher life form, and whether the existence of the Plant Breeders'
Rights Act precludes patent protection were also raised in arguments. Since the Monsanto patent has no claims for the entire
plant, the Court need not deal with these issues. However, if it elects to do so, it will be interesting to see how the patentability
of life forms fares with genetically modified canola compared to the conscious and sentient oncomouse. Depending upon the
outcome, Parliament may be called upon for a legislative fix. In the meantime, as a practical matter,
higher life forms (at least mammals) cannot be patented, although the Court of Appeal judgment in Monsanto supports the position
that a transgenic higher life form still infringes the claims to the cell lines and plasmids.
Canada also has a provision in its Food and Drug Act Regulations - presumably intended to implement Canada's
international obligations - relating to undisclosed information submitted to governments for regulatory approval.6 As judicially interpreted, since the Minister does not "physically examine" the innovator's dossier when considering a generic
manufacturer's submission for approval, typically no period of data protection will apply to an innovator's data.7 As such, this data is available for the purposes of bioequivalence comparisons by generic manufacturers. This is a source
of concern to industry innovators and seen to present a serious competitive disadvantage for Canada as compared to other developed
A Canadian canola field in bloom.
Spending: IP's Rising Costs
As of January 1, it also costs more to obtain IP protection for biotech innovations and products, whether a life form or otherwise.
After years of holding fees flat, CIPO announced significant fee increases for all intellectual property, most of which are
applicable immediately.8-10 According to CIPO, the fees remain significantly less than in other jurisdictions such as the US, Europe, Japan, and Australia.
CIPO also has proposed a legislative fix to address the Dutch Industries decision, which effectively invalidated hundreds
of Canadian patents. The Federal Court of Appeal held that the Commissioner of Patents acted without jurisdiction in accepting
retroactive supplemental payments from large entities that had inadvertently paid at the small entity scale - although there
was a longstanding practice of accepting such payments. The supplemental payment was the difference between the large and
small entity fees. Draft legislation to cure these patents is on CIPO's website for comment until March 31, 2004.